Nintedanib in Idiopathic Pulmonary Fibrosis: Tolerability and Safety in a Real Life Experience in a Single Centre in Patients also Treated with Oral Anticoagulant Therapy

Idiopathic pulmonary fibrosis (IPF) is a rare and severe disease with a median survival of ~3 years. Nintedanib (NTD) has been shown to be useful in controlling interstitial lung disease (ILD) in IPF. Here we describe the experience of NTD use in IPF in a real-life setting. Objective. Our objective...

Descripción completa

Detalles Bibliográficos
Autores principales: Ruaro, Barbara, Gandin, Ilaria, Pozzan, Riccardo, Tavano, Stefano, Bozzi, Chiara, Hughes, Michael, Kodric, Metka, Cifaldi, Rossella, Lerda, Selene, Confalonieri, Marco, Baratella, Elisa, Confalonieri, Paola, Salton, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9959830/
https://www.ncbi.nlm.nih.gov/pubmed/37259452
http://dx.doi.org/10.3390/ph16020307

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9959830/
https://www.ncbi.nlm.nih.gov/pubmed/37259452
http://dx.doi.org/10.3390/ph16020307

Ejemplares similares